

Newest Drugs Of Lung Cancer That's Approved In 2020 (Article Review)

Zainab Sajid Mohammed¹, Wijdan Rajh Hamza Al-Kraity² and Hawraa Natiq Kabroot AL-Fatlawy³

¹Faculty of Pharmacy , Universty of Kufa , Najaf , Iraq .

^{2,3} Faculty of Medicine , University of Kufa , Najaf , Iraq.

E-mail zainabs.hameedi@uokufa.edu.iq, wijdanr.alkraity@uokufa.edu.iq, hawraan.alfatlawy@uokufa.edu.iq

ABSTRACT

Background: Male patient incidence rates have been declining in most affluent countries since the mid-1990s, while female patient incidence rates have been steadily rising. As a result, lung cancer incidence rates in male and female patients have converged in the United States and other industrialized countries, particularly among the younger population. Variances in sex-based lung cancer incidence may be due to sex-specific differences in histological subtypes of lung cancer, as well as changes in smoking prevalence. Tobacco use, a family history of cancer, past lung disorders, and exposure to secondhand smoke, radon, asbestos, arsenic, air pollution, or occupational carcinogens are all common risk factors for lung cancer. Lung cancer subgroups have diverse epidemiological and prognostic characteristics. Small cell lung cancer (SCLC) and squamous cell carcinoma have both been linked to smoking as a major risk factor. In the Western population, smoking is responsible for more than 80% of lung cancer etiology. Lung cancer has been reduced as a result of tobacco control measures such as higher cigarette taxes and pricing, health warnings on packaging, and smoking cessation counseling, as well as a comprehensive ban on tobacco advertising. Adenocarcinoma, on the other hand, is more common in Asians, particularly among females and never-smokers. There is extensive data on the prevalence of EGFR mutations in adenocarcinoma patients, with the highest EGFR mutation frequency of 47 percent in Asia-Pacific and the lowest frequency of 12 percent in Oceania. The development of lung adenocarcinoma in Asian nonsmokers has been linked to strong exposure-response correlations with secondhand smoke and cooking gases, according to studies conducted in China and Hong Kong. Cancer registries that track the efficacy of cancer prevention and treatment techniques are critical for assessing the present cancer burden on healthcare systems and monitoring the efficacy of cancer prevention and treatment strategies. In terms of lung cancer epidemiology in Taiwan, worldwide cancer surveillance data was inadequate, and material from prior studies had grown outdated. We were able to update the changes in the prevalence, incidence, and overall survival of individuals with cancer in this population-based epidemiologic investigation.

Keywords: Lung Cancer Treatments , SCLC, And NSCLC

Article Information

Received: June 03, 2023; Revised: July 16, 2023; Online: August , 2023

INTRODUCTION

Lung cancer, also known as lung carcinoma, is a malignant lung tumor marked by uncontrolled cell proliferation in the lungs [1,2]. This makes it the leading cause of cancer-related death in men and the second leading cause of cancer-related death in women, after breast cancer [3]. Long-term tobacco smoking (85%)[1] is a contributing factor, with 10 to 15% of instances occurring in people who have never

smoked[4]. A combination of circumstances, including exposure to random gas, asbestos, secondhand smoke, or other forms of air pollution, are frequently responsible for these cases [5]. Small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) are the two main kinds of (cancer)[6].

Coughing (including bloody coughing), weight loss, shortness of breath, and chest pain are the most prevalent clinical manifestations[7]. Chest radiography and computed tomography (CT) scans are used to make the diagnosis [1], and the diagnosis is confirmed with bronchoscopy or CT-guided biopsy [8]. Surgery, chemotherapy, and radiography are all common treatments. NSCLC stands for Non-Small Cell Lung Cancer. Smoking and air pollution are two risk factors that can be avoided. Bronchioloalveolar carcinoma is a kind of adenocarcinoma that grows in a lepidic pattern with little stromal or vascular invasion. The existence of a pure ground-glass nodule on radiography, a nodule or mass with an air bronchogram, or persistent masslike consolidation despite antimicrobial treatment should all point to the diagnosis. Despite the fact that bronchioloalveolar carcinoma is more frequently linked with a high rate of false-negative findings on FDG PET, its staging is similar to that of other non-small cell lung cancer subtypes. According to reports, pure bronchioloalveolar carcinoma accounts for about 5% of all non-small cell lung cancer tumors [16].

Malignant carcinoid tumors account for about 1%–2% of all resected lung malignancies and are extremely rare. Although the TNM staging method has not previously applied to carcinoid tumors, the 7th edition advises that they be included because all three characteristics are useful in predicting prognosis. Lung cancer staging is a measurement of the extent to which the cancer has spread from its original site. [12] It's one of the elements that influences lung cancer prognosis and treatment options. [13] [12] The TNM classification is used to determine the stage of non-small-cell lung cancer (NSCLC) (tumor, node, metastasis). This is determined by the size of the initial tumor, the presence of lymph nodes, and the presence of distant metastases. [14]. A group is allocated using the TNM descriptions, spanning from occult cancer to stages 0, IA (one-A), IB, IIA, IIB, IIIA, IIIB, and IV (four). This stage group aids in therapy selection and

prognosis estimation. [15]. SCLC has generally been defined as "limited stage" (restricted to one-half of the chest and within the limits of a single tolerable radiation field) or "extensive stage" (confined to the entire chest and beyond the scope of a single tolerable radiotherapy field) (more widespread disease). [14] The TNM classification and grouping, on the other hand, are beneficial in estimating prognosis. [15]

Clinical staging and surgical staging are the two main forms of staging evaluations for both NSCLC and SCLC. Before undergoing decisive surgery, clinical staging is conducted. It is based on imaging examinations (such as CT scans and PET scans) as well as biopsy data. Surgical staging is assessed before, during, and after the procedure. It's based on a combination of surgical and clinical findings, including thoracic lymph node surgical sample. [15] If the cancer spreads to the airways, it can restrict airflow, making it harder to breathe. The obstruction can also cause secretions to build up behind the blockage, raising the risk of pneumonia. [1]. Depending on the type of tumor, symptoms that are not caused by the presence of cancer locally may initially draw attention to the condition. [18] Hypercalcemia, syndrome of inappropriate antidiuretic hormone (SIADH, abnormally concentrated urine and diluted blood), and ectopic pregnancy are all possible side effects of lung cancer.

Many of the signs and symptoms of lung cancer (such as loss of appetite, weight loss, fever, and exhaustion) are vague. [21] By the time people notice symptoms and seek medical help, the disease has often spread beyond the original spot. [19] Weight loss, bone pain, and neurological symptoms all indicate the existence of metastatic illness (headaches, fainting, convulsions, or limb weakness). (17) The brain, bone, adrenal glands, opposite lung, liver, pericardium, and kidneys are all common sites of spread. [19] About 10% of persons with lung cancer have no symptoms when they are diagnosed; these tumours are discovered by chance during routine chest radiography. [20].

Incidence and Epidemiology

According to the most recent GLOBOCAN figures, 2,094,000 new instances of lung cancer were detected worldwide in 2018, making it the most common cancer. Lung cancer is the second most prevalent cancer in men, after prostate cancer, and the second most frequent cancer in women, with an estimated 1,369,000 cases. According to the program, 229,000 new instances of lung cancer would be diagnosed in the United States in 2020, accounting for 12.7 percent of all cancer diagnoses. Because of smoking cessation, the current incidence of 45.6/100,000 is down from a high of 69.5/100,000 in 1992.

While many Western countries have witnessed a similar trend, developing countries like China and the former Soviet Union have not had the same success with smoking cessation and lung cancer incidence [24]. In China, 65 percent of males start smoking by their mid-20s, indicating that lung cancer incidence will continue to rise for decades [23]. The global incidence of lung cancer is increasing as a result of increased industrialization and access to tobacco [25].

Treatments

Surgery, radiotherapy, or chemotherapy, or a combination of one or all of these, have been the mainstays of treatment for the past 50 years. In the first instance, Techniques, such as preoperative staging, have grown significantly refined as the primary method to offer a chance for cure. Radiotherapy administration has also advanced, with larger dose treatments becoming more practical, improved field design, and more focused targeting. Chemotherapy has also progressed, with virtually none of the drugs used in the 1950s–1970s being used today, as well as a greater understanding of optimal timing, therapy duration, and attention to side effects and quality of life. Despite this, the 1- and 5-year survival rates for all cancer patients have remained relatively constant over the last 30 years (Figure 1). The use of particular tumor antagonists in targeted therapy could be a future treatment option. In addition, patients with lung cancer are increasingly receiving care and making decisions as part of a multidisciplinary team that includes thoracic physicians, surgeons, radiation and medical oncologists, radiologists, pathologists, and palliative care and lung cancer expert nurses. This business cases [26].




Figure 1: Shows the 1- and 5-year survival rates for all lung cancer cases in the UK during the previous 30 years. 1 year for light bars, 1 year for dark bars, 5 years for medium dark bars, 5 years for medium light bars, 5 years for medium light bars, 5 years for medium light bars, 5 years for medium light bars, 5 years for medium light bars, 5 years for medium light bars, 5 years for medium light bars.

Lung cancer has surpassed heart disease as China's third biggest cause of mortality

The Lancet published China's burden of disease data online in June 2019, spanning nearly 30 years [27]. Lung cancer has overtaken strokes and ischemic heart disease as China's third largest cause of death, according to data released by Professor Xiaofeng Liang of the Chinese Center for Disease Control and Prevention (IHD). Increases in age-standardized mortality and years of life lost (YLLs) in lung cancer were observed between 1990 and 2017, resulting in a shift in ranking from 13th in 1990 to third in 2017. This tendency and current circumstances suggest that lung cancer prevention and control should be done in the same way that prevalent disorders like diabetes and obesity are managed.

A meta-analysis of data from ten prospective cohort studies conducted by Xiao-Ou Shu's team at Vanderbilt University [28], with a total of 1.44 million participants and 8.6 years of follow-up, was published in JAMA Oncology in October 2019 [29]. Dietary fiber and yogurt eating were linked to a lower risk of lung cancer, according to the findings. The two groups with the highest fiber and yogurt intake had a reduced risk of lung cancer (17 percent and 19 percent, respectively) than the group with the lowest intake. When comparing those who did not consume yogurt and had the lowest fiber intake to those who did consume yogurt and had the highest fiber intake, the risk of lung cancer was lowered by 33%. Furthermore, young adults may benefit more from dietary fiber and yogurt eating.

Liquid biopsy (LBx) is intended to be employed as a lung cancer early detection method.

At the ASCO and ESMO conferences, the preliminary results of the Circulating Cell-free Genome Atlas (CCGA) Study were presented [30,31]. Signals from 12 malignancies, including lung cancer, can be detected at an early stage by integrating three prototype assays [whole-genome bisulfite (WGBS), whole-genome sequencing

(WGS), and focused (507 gene) sequencing]. This approach had a 55 percent overall detection rate (sensitivity) for all stages and types of malignancies, and the tissue of origin (TOO) localisation was likewise highly accurate. Early-stage cancer (stages I–III) detection results were positive, with sensitivity of 32 percent, 76 percent, and 85 percent for stages I, II, and III, respectively. This is in line with the preliminary findings of the CCGA lung cancer trial, which were presented at the ASCO annual meeting last year and revealed a diagnostic breakthrough.

NADIM was the first multicenter trial to combine conventional chemotherapy (CT) with an immuno-oncology drug (IO) in a neoadjuvant context for patients with stage IIIA cancer. Preoperative treatment consisted of three cycles of NV + paclitaxel + carboplatin, followed by adjuvant NV treatment for one year after surgery. Chemotherapy combined with immunotherapy was well tolerated, and 41 patients underwent surgery, all of whom had R0 resection. After neoadjuvant CT+IO, downstaging was seen in 90% of cases, the MPR rate was 83 percent, and the pCR rate was 71 percent. The imaging PR rate was 71 percent, and the CR rate was 7 percent, according to RECIST (Response Evaluation Criteria in Solid Tumors). Due to progressive disease (PD) or safety concerns, no participants withdrew from the study prior to surgery. Neoadjuvant immunotherapy, especially when paired with chemotherapy, produced a stunning pathological response rate, which will significantly alter the treatment approach for early-stage lung cancer.

Concurrent immunotherapy and chemoradiotherapy

The current topic of contention is whether immunotherapy and chemoradiotherapy can be used together. According to a study presented at the ASCO annual meeting 2019, atezolizumab combined with concurrent chemoradiotherapy had favorable safety in patients with locally advanced NSCLC, implying that concurrent

chemoradiotherapy plus immunotherapy does not increase toxicity when compared to chemoradiotherapy followed by immunotherapy. The PACIFIC2 trial is now underway, with the goal of determining the influence on efficacy of bringing immunotherapy to the same stage as chemoradiotherapy.

Is prophylactic cranial irradiation necessary for patients with locally advanced NSCLC? (PCI) JAMA Oncology [41] provided an update on the RTOG 0214 trial, a prospective, randomized, multicenter phase 3 investigation of patients with locally advanced NSCLC. Despite PCI therapy significantly reducing the incidence of brain metastasis (BM) and remarkably improving disease-free survival (DFS) compared to the observation group in patients without disease progression after local therapy, there was no improvement in disease-free survival (DFS) in patients without disease progression after local therapy.

REFERENCES:

- [1]. Lung Carcinoma:Tumors of the Lungs.Merck Manual Professional Edition.online edition. Retrieved 15th August 2007.
- [2]. Non-small cell lung cancer Treatment-Patient Version(PDQ®).NCL.May 12,2015.retrieved 5 March 2016.
- [3]. World Cancer Report 2014.World Health Organization.2014.pp.Chapter 1.1.ISBN 9283204298.
- [4]. Thun MJ,HannanLM,AdamsCambellLL,etal.Lung cancer occurrence in never smokers:an analysis of 13 cohorts and 22 cancer registry studies.PLoSMed.2008;5(9):1185
- [5]. O'Reilly KM,MclaughlinAM,BeckettWS,etal.Asbestos related lung disease.AmericanFamily Physician.2007;75(5):683-688.
- [6]. Lung Cancer-patient Version.NCI.Retrieved 5 March 2016.
- [7]. HomL,LovlyCM,Johnson DH(2015).Chapter 107.Neoplasm of Lung.In Kasper DL;Hauser, SL,JamesonJL,Fauci AS,Longo DL,LoscalzoJ. Harrison's Principles ofInternal Medicine(19th ed.)McGraw-Hill.ISBN 978-0-07-180216-1.
- [8]. Lu C,OnnA,VaporciyanAA,et al.(2010).78:Cancer of Lung.Holland-Frei CancerMedicine(8th ed.).People's Medical Publishing House.ISBN 978-1-60795-014-1.
- [9]. Chapman S,RobinsonG,StreadlingJ,et al(2009).Chapter 31.Oxford Handbook of Respiratory Medicine(2nd ed.)Oxford University Press.ISBN 978-0-19-954516-2.
- [10]. Lung Cancer Prevention-Patient Version(PDQ R)NCI.November 4,2015.Retrieved 5 March 2016.
- [11]. Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of bronchopulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for Lung Cancer. J Thorac Oncol 2008;3(11):1213–1223.
- [12]. Connolly JL, Goldsmith JD, Wang HH, et al. (2010). "37: Principles of Cancer Pathology". Holland-Frei Cancer Medicine (8th ed.). People's Medical Publishing House. ISBN 978-1-60795-014-1.
- [13]. Horn L, Lovly CM (2018). "Chapter 74: Neoplasms of the lung". In Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (eds.). Harrison's Principles of Internal Medicine (20th ed.). McGraw-Hill. ISBN 978-1259644030.
- [14]. Rami-Porta R, Crowley JJ, Goldstraw P (February 2009). "The revised TNM staging system for lung cancer" (PDF). Annals of Thoracic and Cardiovascular Surgery. 15 (1): 4–9. PMID 19262443. Archived(PDF) from the original on 9 May 2012.
- [15]. Lu C, Onn A, Vaporciyan AA, et al. (2010). "Chapter 78: Cancer of the Lung". Holland-Frei Cancer

Medicine (8th ed.). People's Medical Publishing House. ISBN 978-1-60795-014-1.

[16]. Arenberg D; American College of Chest Physicians. Bronchioloalveolar lung cancer: ACCP evidencebased clinical practice guidelines. 2nd ed. Chest 2007;132(3 suppl):306S–313S.

[17]. Horn L, Lovly CM (2018). "Chapter 74: Neoplasms of the lung". In Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (eds.). Harrison's Principles of Internal Medicine(20th ed.). McGraw-Hill. ISBN 978-1259644030.

[18]. Honnorat J, Antoine JC (May 2007). "Paraneoplastic neurological syndromes". Orphanet Journal of Rare Diseases. 2 (1): 22. doi:10.1186/1750-1172-2-22. PMC 1868710. PMID 17480225.

[19]. Frederick L G (2002). AJCC cancer staging manual. Berlin: Springer-Verlag. ISBN 978-0-387-95271-0.

[20]. Collins LG, Haines C, Perkel R, Enck RE (January 2007). "Lung cancer: diagnosis and management". American Family Physician. 75 (1): 56–63. PMID 17225705. Archived from the original on 29 September 2007.

[21]. Lu C, Onn A, Vaporciyan AA, et al. (2010). "Chapter 78: Cancer of the Lung". Holland-Frei Cancer Medicine (8th ed.). People's Medical Publishing House. ISBN 978-1-60795-014-1.

[22]. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and

mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.

[23]. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. Lyon, France. Available at: <https://gco.iarc.fr/today> (Accessed: 15.09.2020).

[24]. Howlander N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975–2016. National Cancer Institute, 2019.

[21.....]. Doll R. Evolution of knowledge of the smoking epidemic. Tob Sci Policy Public Heal 2010. doi:10.1093/acprof:oso/9780199566655.003.0001.

[25].Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health 2019; 85: 8.

[26]Alberts MW, Bepler G, Hazelton T, Ruckdeschel JC, Williams JH. Practice organization. Chest 2003;123:332s–337s.

[27].Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global

Burden of Disease Study 2017. Lancet 2019;394:1145-58. 10.1016/S0140-6736(19)30427-1 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[28]. Yang JJ, Yu D, Xiang YB, et al. Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis. JAMA Oncol 2019. [Epub ahead of print]. [PMC free article] [PubMed] [Google Scholar]

[29].Dai J, Lv J, Zhu M, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Lancet Respir Med 2019;7:881-91. 10.1016/S2213-

2600(19)30144-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[30]. Cohn AL, Seiden M, Kurtzman KN, et al. The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals. J Clin Oncol 2019;37:abstr 5574.

[31].Oxnard GR, Klein EA, Seiden MV, et al. Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA). Ann Oncol 2019;30:912

10.1093/annonc/mdz394.074 [CrossRef]
[Google Scholar]

[32].Liang W, Zhao Y, Huang W, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). *Theranostics* 2019;9:2056-70.

10.7150/thno.28119 [PMC free article]
[PubMed] [CrossRef] [Google Scholar]

[33].Kwiatkowski DJ, Rusch VW, Chaft JE, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). *J Clin Oncol* 2019;37:abstr 8503.

[34].Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. *J Clin Oncol* 2019;37:abstr 8504.

[35].Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment. *J Clin Oncol* 2019;37:abstr 8509.

[36].Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. *Lancet Oncol* 2019;20:494-503. 10.1016/S1470-2045(18)30896-9 [PubMed] [CrossRef] [Google Scholar]

[37].Zeng Y, Mayne N, Yang CJ, et al. A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. *Ann Surg Oncol* 2019;26:2053-62. [PubMed] [Google Scholar]

[38].Zhao Y, Wang W, Liang H, et al. The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-

Analysis. *Ann Thorac Surg* 2019;107:1866-75.10.1016/j.athoracsur.2018.11.024 [PubMed] [CrossRef] [Google Scholar]

[39].Gray JE, Villegas AE, Daniel DB, et al. Three-year overall survival update from the PACIFIC trial. *J Clin Oncol* 2019;37:abstr 8526.

[40]Hui R, Özgüroğlu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. *Lancet Oncol* 2019;20:1670-80. 10.1016/S1470-2045(19)30519-4 [PubMed] [CrossRef] [Google Scholar]

[41].Sun A, Hu C, Wong SJ, et al. Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2019;5:847-55. 10.1001/jamaoncol.2018.7220 .